Management of Elevated INR in Liver Failure
Introduction to Coagulopathy Management
- In patients with liver failure, routine correction of elevated INR with fresh frozen plasma (FFP) or vitamin K is not recommended unless there is active bleeding or an urgent invasive procedure is planned, as these interventions do not improve outcomes and may cause harm 1, 2, 3
- Despite abnormal coagulation tests, clinically significant spontaneous bleeding is rare in liver failure and often related to other factors such as portal hypertension rather than coagulopathy 1, 2
Management Approach for Elevated INR
- Prophylactic correction of INR with FFP should be abandoned in the absence of bleeding 1, 2
- Routine administration of vitamin K to correct INR in liver failure is not supported by evidence 1, 2
- Subcutaneous vitamin K does not modify coagulation parameters in liver disease 1, 2
Treatment Considerations
- For active clinically significant bleeding, targeted blood product replacement may be considered 3
- For invasive procedures where local hemostasis is not possible, correction may be considered on a case-by-case basis 4
- Consider correction only for high-risk procedures where local hemostasis is not possible 4
- Intravenous vitamin K may temporarily correct INR in cholestatic liver disease but has limited effect in other forms of liver failure 1, 2
Specific Treatment Options
- Intravenous vitamin K may temporarily correct INR in cholestatic liver disease but has minimal effect in other forms of liver failure 1, 2
- Only 14% of patients with cirrhosis achieve complete INR correction with FFP transfusions 1, 2
- FFP does not modify thrombin generation despite shortening the INR 1, 2
- Potential harms of FFP include transfusion-associated circulatory overload, transfusion-related acute lung injury, and allergic reactions 5
- PCCs provide more rapid and effective INR correction than FFP but are considered off-label use in liver failure 4, 5
- Patients with liver failure show an exaggerated procoagulant response to PCCs, with increased thrombin generation by 150-270% compared to 97% in healthy individuals 4, 5
- Risk of thromboembolic events (5.5%) has been reported in patients with cirrhosis receiving PCCs 4, 5
- Routine use of PCCs to decrease procedure-related bleeding is discouraged 4, 5